Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune hepatitis.

P Obermayer-Straub1, C P Strassburg, M P Manns

  • 1Department of Gastroenterology and Hepatology, Hannover Medical School, Germany.

Journal of Hepatology
|March 23, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The challenge of replicating putative genetic risk factors in a population-based database.

Journal of gastroenterology and hepatology·2024
Same author

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.

ESMO open·2023
Same author

TLR agonists enhance responsiveness of inflammatory innate immune cells in HLA-B*57-positive HIV patients.

Journal of molecular medicine (Berlin, Germany)·2020
Same author

Dye chromoendoscopy leads to a higher adenoma detection in the duodenum and stomach in patients with familial adenomatous polyposis.

Endoscopy international open·2020
Same author

Parameters predicting COVID-19-induced myocardial injury and mortality.

Life sciences·2020
Same author

Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?

HIV medicine·2020
Same journal

Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44<sup>+</sup>pDC crosstalk.

Journal of hepatology·2026
Same journal

Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration.

Journal of hepatology·2026
Same journal

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Journal of hepatology·2026
Same journal

Response to "Single-nucleus and spatial transcriptomic analyses reveal intra-tissue heterogeneity of PNPLA3".

Journal of hepatology·2026
Same journal

One-stop liquid biopsy: Can a single blood sample reveal the full spectrum of liver disease?

Journal of hepatology·2026
Same journal

Nocturnal insulin resistance and reduced insulin availability in human MASLD.

Journal of hepatology·2026
See all related articles

Autoimmune hepatitis (AIH) is a rare liver disease with subtypes based on autoantibodies. While current treatments offer high survival, new regimens are needed due to treatment failures and lack of permanent remission.

Area of Science:

  • Hepatology
  • Immunology
  • Genetics

Background:

  • Autoimmune hepatitis (AIH) is a rare chronic liver disease predominantly affecting females, characterized by hypergammaglobulinemia, autoantibodies, and HLA associations.
  • AIH presents with distinct subtypes (Type 1: ANA/SMA; Type 2: LKM; Type 3: SLA/LP), differing in autoantibody profiles, age of onset, clinical course, and treatment response.
  • AIH Type 2 typically affects pediatric patients, exhibiting a more severe course, higher relapse rates, and increased progression to cirrhosis compared to Types 1 and 3.

Purpose of the Study:

  • To review the current understanding of autoimmune hepatitis (AIH) subtypes, clinical characteristics, and treatment strategies.
  • To highlight the limitations of existing immunosuppressive therapies and the unmet need for novel treatment regimens.
  • To explore the genetic and environmental factors implicated in the etiology of AIH.

Related Experiment Videos

Main Methods:

  • Literature review of autoimmune hepatitis (AIH) classification, clinical features, and therapeutic approaches.
  • Analysis of autoantibody patterns (ANA, SMA, LKM, SLA, LP) for AIH subtyping.
  • Examination of genetic predispositions (HLA, C4A alleles) and environmental triggers (drugs, viruses) in AIH pathogenesis.

Main Results:

  • AIH subtypes exhibit distinct autoantibody profiles, age distributions, and prognoses, with Type 2 generally having a poorer outcome.
  • Current standard treatments (prednisone alone or with azathioprine) achieve high survival rates but are associated with a 13% failure rate and incomplete remission.
  • Genetic factors (HLA-DR3/DR4, C4A deletions, female gender) and environmental triggers (certain drugs, viral infections) are implicated in AIH development, potentially through molecular mimicry or adduct formation.

Conclusions:

  • Despite effective immunosuppression, the persistent treatment failure rate and inability to achieve permanent remission in AIH underscore the critical need for developing alternative therapeutic strategies.
  • Understanding the complex interplay of genetic predisposition and environmental factors is crucial for elucidating AIH etiology and designing targeted therapies.
  • Further research into novel treatment regimens is essential to improve long-term outcomes and achieve sustained remission for patients with autoimmune hepatitis.